Wei Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wei Gao has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Qiang Li
Department of Respiratory and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University
12 shared publications Ximing Liao
Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China
12 shared publicationsMuyun Wang
Shanghai East hospital, School of Medicine, Tongji University, Shanghai, China
11 shared publicationsDi Wu
Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, No. 150 Jimo Road, Pudong, Shanghai, 200092, P.R. China
9 shared publicationsJing Gao
Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China
9 shared publicationsKun Wang
Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China
7 shared publications
Latest Publications
- 22 October 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 191 (Pt 1) , 117583
Neuroinflammatory mechanisms and pharmacological modulation of the lung-brain axis in post-viral pulmonary sequelae
- 22 October 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 191 (Pt 1) , 117583
Neuroinflammatory mechanisms and pharmacological modulation of the lung-brain axis in post-viral pulmonary sequelae
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA4682
ROCK1-PAD axis drives airway epithelial dysfunction in relapsing polychondritis: a patient-derived 3D model study
Background: Relapsing polychondritis (RP) with airway involvement is a devastating disease leading to structural collapse and respiratory failure. Research is hampered by the lack of simple, stable animal models. We established a patient-derived 3D lung model to elucidate RP airway pathogenic mechanisms and identify therapeutic targets. Methods: Primary airway epithelial cells obtained via bronchial brushing from RP patients and healthy controls were differentiated at air-liquid interface (ALI) to form 3D epithelia. Morphology was assessed by histology. RNA sequencing of ALI cultures and plasma proteomics of patients were performed. Functional validation was conducted using specific inhibitors targeting the identified pathway. Results: Compared to controls, RP epithelia exhibited disrupted architecture, hyperproliferation, and increased senescence markers (e.g., p16, SA-β-gal). Multi-omics integration revealed significant activation of the ROCK1 signalling pathway in RP epithelia. This activation drove upregulation of peptidylarginine deiminase (PAD), leading to accelerated histone citrullination accumulation, a novel mechanism linking to cellular senescence and dysfunction. Targeted intervention using a ROCK1 inhibitor or a PAD inhibitor during ALI differentiation for two weeks significantly improved epithelial cell alignment, morphology, and barrier function in RP cultures. Conclusions: This patient-derived 3D model overcomes historical model limitations. The ROCK1-PAD-histone citrullination axis drives RP airway epithelial senescence and dysfunction, and its pharmacological inhibition rescues epithelial defects, highlighting ROCK1/PAD as promising therapeutic targets for treatment-refractory RP airway disease.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA4682
ROCK1-PAD axis drives airway epithelial dysfunction in relapsing polychondritis: a patient-derived 3D model study
Background: Relapsing polychondritis (RP) with airway involvement is a devastating disease leading to structural collapse and respiratory failure. Research is hampered by the lack of simple, stable animal models. We established a patient-derived 3D lung model to elucidate RP airway pathogenic mechanisms and identify therapeutic targets. Methods: Primary airway epithelial cells obtained via bronchial brushing from RP patients and healthy controls were differentiated at air-liquid interface (ALI) to form 3D epithelia. Morphology was assessed by histology. RNA sequencing of ALI cultures and plasma proteomics of patients were performed. Functional validation was conducted using specific inhibitors targeting the identified pathway. Results: Compared to controls, RP epithelia exhibited disrupted architecture, hyperproliferation, and increased senescence markers (e.g., p16, SA-β-gal). Multi-omics integration revealed significant activation of the ROCK1 signalling pathway in RP epithelia. This activation drove upregulation of peptidylarginine deiminase (PAD), leading to accelerated histone citrullination accumulation, a novel mechanism linking to cellular senescence and dysfunction. Targeted intervention using a ROCK1 inhibitor or a PAD inhibitor during ALI differentiation for two weeks significantly improved epithelial cell alignment, morphology, and barrier function in RP cultures. Conclusions: This patient-derived 3D model overcomes historical model limitations. The ROCK1-PAD-histone citrullination axis drives RP airway epithelial senescence and dysfunction, and its pharmacological inhibition rescues epithelial defects, highlighting ROCK1/PAD as promising therapeutic targets for treatment-refractory RP airway disease.
- Open Access
- 4 July 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1)
Dopamine signaling reprograms macrophage FAO to alleviate acute lung injury by inhibiting NETosis via the CXCL10-CXCR3 axis
Background: Dysregulated innate immunity and oxidative stress drive the pathogenesis of acute lung injury/acute respiratory distress syndrome (ALI/ARDS), yet master endogenous regulators that orchestrate inflammation resolution remain elusive. Methods: This study employed public database mining, clinical data investigation, murine disease models, mouse bone marrow-derived macrophages and neutrophils, and human macrophages from healthy donors and ARDS patients, to investigate the dynamic changes of the dopaminergic signaling system in the acute pulmonary inflammatory environment and its role in regulating macrophage metabolism and neutrophil extracellular trap formation (NETosis). Results: Public database mining and experimental data reveal accelerated dopamine (DA) turnover during ALI. DA, signaling via D1-like receptors, reprograms macrophage metabolism by enhancing carnitine palmitoyltransferase 1 A (CPT1A)-dependent fatty acid oxidation (FAO) and mitochondrial fitness, which is coupled with the suppression of MAPK/NF-κB and NLRP3 inflammasome activation. These modulated macrophages restrain neutrophilic inflammation by secreting IL-10 to inhibit the CXCL10-CXCR3 axis, thereby curtailing neutrophil hyperactivation and pathogenic NETosis. Crucially, this protective mechanism is conserved in human macrophages from both healthy donors and ARDS patients. Conclusion: Our findings establish DA as a therapeutic target for recalibrating innate immunity in ALI, providing a mechanistically grounded framework for targeting dopaminergic signaling to resolve dysregulated inflammation, with exploratory preclinical translational implications for ALI/ARDS therapy.
- 4 July 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1)
Open AccessDopamine signaling reprograms macrophage FAO to alleviate acute lung injury by inhibiting NETosis via the CXCL10-CXCR3 axis
Background: Dysregulated innate immunity and oxidative stress drive the pathogenesis of acute lung injury/acute respiratory distress syndrome (ALI/ARDS), yet master endogenous regulators that orchestrate inflammation resolution remain elusive. Methods: This study employed public database mining, clinical data investigation, murine disease models, mouse bone marrow-derived macrophages and neutrophils, and human macrophages from healthy donors and ARDS patients, to investigate the dynamic changes of the dopaminergic signaling system in the acute pulmonary inflammatory environment and its role in regulating macrophage metabolism and neutrophil extracellular trap formation (NETosis). Results: Public database mining and experimental data reveal accelerated dopamine (DA) turnover during ALI. DA, signaling via D1-like receptors, reprograms macrophage metabolism by enhancing carnitine palmitoyltransferase 1 A (CPT1A)-dependent fatty acid oxidation (FAO) and mitochondrial fitness, which is coupled with the suppression of MAPK/NF-κB and NLRP3 inflammasome activation. These modulated macrophages restrain neutrophilic inflammation by secreting IL-10 to inhibit the CXCL10-CXCR3 axis, thereby curtailing neutrophil hyperactivation and pathogenic NETosis. Crucially, this protective mechanism is conserved in human macrophages from both healthy donors and ARDS patients. Conclusion: Our findings establish DA as a therapeutic target for recalibrating innate immunity in ALI, providing a mechanistically grounded framework for targeting dopaminergic signaling to resolve dysregulated inflammation, with exploratory preclinical translational implications for ALI/ARDS therapy.
- Open Access
Deficiency of Mitochondrial Fatty Acid Enzyme, CPT1A , Underlies Airway Epithelial Barrier Dysfunction in Severe Asthma
Background: Mitochondrial fatty acid oxidation through carnitine palmitoyltransferase‐1A (CPT1A) leads to ATP generation. We examined its role in regulating permeability and mitochondrial metabolic homeostasis of airway epithelial cells in asthma. Methods: Primary nasal epithelial cells (NECs) from healthy controls and severe asthma (SA) patients in air‐liquid interface (ALI) were exposed to CPT1A siRNA/ CPT1A overexpression lentiviral/L‐carnitine (LCA). Epithelial TEER and FITC‐dextran transport were measured. Bronchial biopsies from healthy and SA subjects and house dust mite (HDM) asthma mouse model were also studied. Results: In NECs‐ALI and in bronchial epithelial cells (BECs) from bronchial biopsies of SA, CPT1A expression was reduced compared to healthy controls. Knock‐down of CPT1A in healthy NECs reduced expression of Occludin and E‐cadherin and impaired epithelial barrier integrity (EBI), while upregulation of CPT1A with CPT1A overexpression lentiviral/LCA in SA‐NECs increased the barrier proteins with improved EBI. CPT1A knockdown in healthy BECs increased release of mtROS, with mitochondrial disruption and activation of ERK1/2‐NF‐κB signaling pathway. These were aggravated with HDM exposure but N‐acetyl‐cysteine and MitoTempo reduced p‐ERK1/2 and p‐P65 activation, as well as EBI with CPT1A knockdown and HDM. In the mouse model, there was decreased airway epithelial CPT1A protein expression, associated with reduced airway hyperreactivity and inflammation, and in Occludin and ZO‐1 expression, effects partly reversed by LCA, with restoration of mitochondrial integrity and EBI. Conclusion: CPT1A maintains epithelial barrier function through restoration of mitochondrial function in asthmatic airway epithelial cells. Restoration of deficient epithelial CPT1A of SA may represent a new treatment approach.
Open AccessDeficiency of Mitochondrial Fatty Acid Enzyme, CPT1A , Underlies Airway Epithelial Barrier Dysfunction in Severe Asthma
Background: Mitochondrial fatty acid oxidation through carnitine palmitoyltransferase‐1A (CPT1A) leads to ATP generation. We examined its role in regulating permeability and mitochondrial metabolic homeostasis of airway epithelial cells in asthma. Methods: Primary nasal epithelial cells (NECs) from healthy controls and severe asthma (SA) patients in air‐liquid interface (ALI) were exposed to CPT1A siRNA/ CPT1A overexpression lentiviral/L‐carnitine (LCA). Epithelial TEER and FITC‐dextran transport were measured. Bronchial biopsies from healthy and SA subjects and house dust mite (HDM) asthma mouse model were also studied. Results: In NECs‐ALI and in bronchial epithelial cells (BECs) from bronchial biopsies of SA, CPT1A expression was reduced compared to healthy controls. Knock‐down of CPT1A in healthy NECs reduced expression of Occludin and E‐cadherin and impaired epithelial barrier integrity (EBI), while upregulation of CPT1A with CPT1A overexpression lentiviral/LCA in SA‐NECs increased the barrier proteins with improved EBI. CPT1A knockdown in healthy BECs increased release of mtROS, with mitochondrial disruption and activation of ERK1/2‐NF‐κB signaling pathway. These were aggravated with HDM exposure but N‐acetyl‐cysteine and MitoTempo reduced p‐ERK1/2 and p‐P65 activation, as well as EBI with CPT1A knockdown and HDM. In the mouse model, there was decreased airway epithelial CPT1A protein expression, associated with reduced airway hyperreactivity and inflammation, and in Occludin and ZO‐1 expression, effects partly reversed by LCA, with restoration of mitochondrial integrity and EBI. Conclusion: CPT1A maintains epithelial barrier function through restoration of mitochondrial function in asthmatic airway epithelial cells. Restoration of deficient epithelial CPT1A of SA may represent a new treatment approach.
- Open Access
- 13 June 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Multicellular crosstalk in neutrophilic asthma: unraveling the pathogenic web of steroid resistance and emerging precision therapies
Background: Neutrophilic asthma (NA) is a severe, glucocorticoid-resistant phenotype. Although it represents a small proportion of asthma cases, it imposes a disproportionate burden due to its poor responsiveness to conventional therapies. Challenging the traditional view of isolated molecular defects, emerging evidence positions steroid resistance in NA as a product of dynamic, self-perpetuating pathogenic networks involving neutrophils, airway epithelial cells, T helper cells, macrophages, and B cells. Main body: This review synthesizes the cellular crosstalk underlying NA, emphasizing how convergent interactions impair glucocorticoid receptor function, a final common pathway to steroid resistance. We critically examine emerging therapeutic strategies that disrupt key network nodes, highlighting a shift from single‑target to rational combination regimens. In parallel, we propose a biomarker‑anchored endotyping framework for precision patient stratification, an essential step toward translating network‑targeted interventions into clinical practice. Finally, we identify major knowledge gaps in NA pathogenesis and steroid resistance, and outline priority directions for future research. Conclusions: This review provides an integrated perspective on the pathogenesis of steroid-refractory NA and offers actionable insights for precision management, aiming to improve clinical care for this severe asthma subtype.
- 13 June 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessMulticellular crosstalk in neutrophilic asthma: unraveling the pathogenic web of steroid resistance and emerging precision therapies
Background: Neutrophilic asthma (NA) is a severe, glucocorticoid-resistant phenotype. Although it represents a small proportion of asthma cases, it imposes a disproportionate burden due to its poor responsiveness to conventional therapies. Challenging the traditional view of isolated molecular defects, emerging evidence positions steroid resistance in NA as a product of dynamic, self-perpetuating pathogenic networks involving neutrophils, airway epithelial cells, T helper cells, macrophages, and B cells. Main body: This review synthesizes the cellular crosstalk underlying NA, emphasizing how convergent interactions impair glucocorticoid receptor function, a final common pathway to steroid resistance. We critically examine emerging therapeutic strategies that disrupt key network nodes, highlighting a shift from single‑target to rational combination regimens. In parallel, we propose a biomarker‑anchored endotyping framework for precision patient stratification, an essential step toward translating network‑targeted interventions into clinical practice. Finally, we identify major knowledge gaps in NA pathogenesis and steroid resistance, and outline priority directions for future research. Conclusions: This review provides an integrated perspective on the pathogenesis of steroid-refractory NA and offers actionable insights for precision management, aiming to improve clinical care for this severe asthma subtype.
- Open Access
- 1 June 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1)
Neutrophilic asthma: advances in experimental models from pathogenesis to therapeutic translation
Background: Neutrophilic asthma (NA) is a severe and therapy-resistant asthma endotype marked by persistent airway inflammation, neutrophil infiltration, and limited response to glucocorticoids. The development of targeted therapies has been hampered by insufficient mechanistic insight and the lack of physiologically relevant experimental models. Main body: This review comprehensively synthesizes current in vivo and in vitro models for NA, discussing their methodologies, mechanistic fidelity, and translational potential. Murine systems provide flexible genetic and induction platforms; rat models reliably replicate steroid resistance; and equine models spontaneously mimic chronic human disease. Advanced in vitro approaches including air–liquid interface cultures, patient-derived organoids and lung-on-a-chip devices, enable precise study of epithelial barrier dysfunction, immune crosstalk, and personalized drug responses. Conclusion: By critically evaluating these tools, our review establishes a foundation for model standardization and underscores their collective role in elucidating NA pathogenesis and advancing precision medicine.
- 1 June 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1)
Open AccessNeutrophilic asthma: advances in experimental models from pathogenesis to therapeutic translation
Background: Neutrophilic asthma (NA) is a severe and therapy-resistant asthma endotype marked by persistent airway inflammation, neutrophil infiltration, and limited response to glucocorticoids. The development of targeted therapies has been hampered by insufficient mechanistic insight and the lack of physiologically relevant experimental models. Main body: This review comprehensively synthesizes current in vivo and in vitro models for NA, discussing their methodologies, mechanistic fidelity, and translational potential. Murine systems provide flexible genetic and induction platforms; rat models reliably replicate steroid resistance; and equine models spontaneously mimic chronic human disease. Advanced in vitro approaches including air–liquid interface cultures, patient-derived organoids and lung-on-a-chip devices, enable precise study of epithelial barrier dysfunction, immune crosstalk, and personalized drug responses. Conclusion: By critically evaluating these tools, our review establishes a foundation for model standardization and underscores their collective role in elucidating NA pathogenesis and advancing precision medicine.
- Open Access
- 23 April 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Dopamine signaling governs macrophage-mediated acute lung injury through JAML/IL-10-coupled mitochondrial regulation
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) remain devastating clinical entities characterized by uncontrolled pulmonary inflamm
- 23 April 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Open AccessDopamine signaling governs macrophage-mediated acute lung injury through JAML/IL-10-coupled mitochondrial regulation
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) remain devastating clinical entities characterized by uncontrolled pulmonary inflamm
- Open Access
- 17 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1650527
Sex differences in immune cells: mechanistic perspectives and clinical correlates in physiology and disease
For decades, sex disparities have been acknowledged to influence immune regulation in health and disease throughout the life span, and contribute to variations in epidemiology, pathophysiology, manifestation, progression, and therapeutic response in multiple disorders. However, the underlying cellular and molecular mechanisms governing these disparities remain understudied. This review articulates the effects of sex as critical regulators of the major causes of morbidity and mortality in diseases. We summarize the key factors driving sex differences, including sexual hormones and sex chromosomes, as well as elaborate how these factors influence physiology and disease, especially by modulating the function and fate of immune cells. Our aim is to disentangle the intricacies of sexually-differentiated immune responses within physiological and pathological contexts, thereby establishing the groundwork for precision medicine approaches customized to sex-specific requirements in clinical settings.
- 17 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1650527
Open AccessSex differences in immune cells: mechanistic perspectives and clinical correlates in physiology and disease
For decades, sex disparities have been acknowledged to influence immune regulation in health and disease throughout the life span, and contribute to variations in epidemiology, pathophysiology, manifestation, progression, and therapeutic response in multiple disorders. However, the underlying cellular and molecular mechanisms governing these disparities remain understudied. This review articulates the effects of sex as critical regulators of the major causes of morbidity and mortality in diseases. We summarize the key factors driving sex differences, including sexual hormones and sex chromosomes, as well as elaborate how these factors influence physiology and disease, especially by modulating the function and fate of immune cells. Our aim is to disentangle the intricacies of sexually-differentiated immune responses within physiological and pathological contexts, thereby establishing the groundwork for precision medicine approaches customized to sex-specific requirements in clinical settings.
- Open Access
- 1 February 2026
- Published by Tsinghua University Press in Nano Research
- Vol. 19 (2)
Harnessing tumor microenvironment immunocytes: Nanomedicine strategies for lung cancer therapy
Lung cancer, characterized by high mortality, demands more precise and efficient treatment strategies, while the tumor microenvironment (TME) plays a pivotal role in its progression and therapy resistance. In recent years, nanomedicine has emerged as a promising approach to reprogram the immunosuppressive TME and enhance antitumor immunity. This review comprehensively summarizes the latest advances in targeting key immunocytes, including antigen-presenting cells (APCs), cytotoxic cells, regulatory T cells (Tregs), tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and tumor-associated neutrophils (TANs), using nanomaterial-based strategies for lung cancer treatment. We discuss the design rationale, targeting mechanisms, and therapeutic benefits of various nanoplatforms, highlighting their potential to improve immune activation and drug delivery while minimizing off-target effects. Additionally, we address current challenges including cellular heterogeneity, inadequate tumor penetration, and immune-related adverse events. Finally, we offer perspectives on the future development of immunocyte-targeted nanomedicines, with an emphasis on biomimetic strategies, multi-target approaches, and clinical translation. This review aims to provide a mechanistic foundation and practical guidance for advancing nano-immunotherapy in lung cancer.
- 1 February 2026
- Published by Tsinghua University Press in Nano Research
- Vol. 19 (2)
Open AccessHarnessing tumor microenvironment immunocytes: Nanomedicine strategies for lung cancer therapy
Lung cancer, characterized by high mortality, demands more precise and efficient treatment strategies, while the tumor microenvironment (TME) plays a pivotal role in its progression and therapy resistance. In recent years, nanomedicine has emerged as a promising approach to reprogram the immunosuppressive TME and enhance antitumor immunity. This review comprehensively summarizes the latest advances in targeting key immunocytes, including antigen-presenting cells (APCs), cytotoxic cells, regulatory T cells (Tregs), tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and tumor-associated neutrophils (TANs), using nanomaterial-based strategies for lung cancer treatment. We discuss the design rationale, targeting mechanisms, and therapeutic benefits of various nanoplatforms, highlighting their potential to improve immune activation and drug delivery while minimizing off-target effects. Additionally, we address current challenges including cellular heterogeneity, inadequate tumor penetration, and immune-related adverse events. Finally, we offer perspectives on the future development of immunocyte-targeted nanomedicines, with an emphasis on biomimetic strategies, multi-target approaches, and clinical translation. This review aims to provide a mechanistic foundation and practical guidance for advancing nano-immunotherapy in lung cancer.
- Open Access
- 19 January 2026
- Published by Taylor & Francis in Redox Report
- Vol. 31 (1) , 2613534
Protective role of fatty acid oxidation against epithelial barrier dysfunction in allergic asthma
Fatty acid oxidation (FAO) is implicated in lung diseases, but its role in bronchial asthma is not fully understood. We investigated its effect on airway epithelial barrier integrity. Using a house dust mite (HDM)-induced murine asthma model and HDM, IL-4, IL-13, or TNF-α stimulated human primary bronchial epithelial cells (BECs) and bronchial epithelial (Beas-2b) cells, we modulated FAO with L-carnitine (agonist) and Etomoxir (inhibitor). BECs and Beas-2b cells were infected with lentivirus-mediated CPT1A shRNA prior to stimulation. Barrier function, mitochondrial oxidative stress, inflammation, and metabolism were assessed. FAO level in lungs negatively correlated with increased inflammation and tissue injury in HDM-induced asthmatic mice (all p < 0.05), while positively regulating tight junction protein expression. In BECs and Beas-2b cells, Etomoxir treatment and CPT1A knockdown exacerbated the impairment of FAO caused by various stimulants (all p < 0.05). Furthermore, FAO negatively regulated HDM/cytokine-induced epithelial barrier damage, hyperactive inflammatory response, and mitochondrial dysfunction in Beas-2b cells (all p < 0.05). In contrast, treatment with L-carnitine significantly alleviated these pathophysiological features in both in vivo and in vitro models. FAO plays a protective role in the occurrence and development of asthma by maintaining airway epithelial cell homeostasis and barrier function.
- 19 January 2026
- Published by Taylor & Francis in Redox Report
- Vol. 31 (1) , 2613534
Open AccessProtective role of fatty acid oxidation against epithelial barrier dysfunction in allergic asthma
Fatty acid oxidation (FAO) is implicated in lung diseases, but its role in bronchial asthma is not fully understood. We investigated its effect on airway epithelial barrier integrity. Using a house dust mite (HDM)-induced murine asthma model and HDM, IL-4, IL-13, or TNF-α stimulated human primary bronchial epithelial cells (BECs) and bronchial epithelial (Beas-2b) cells, we modulated FAO with L-carnitine (agonist) and Etomoxir (inhibitor). BECs and Beas-2b cells were infected with lentivirus-mediated CPT1A shRNA prior to stimulation. Barrier function, mitochondrial oxidative stress, inflammation, and metabolism were assessed. FAO level in lungs negatively correlated with increased inflammation and tissue injury in HDM-induced asthmatic mice (all p < 0.05), while positively regulating tight junction protein expression. In BECs and Beas-2b cells, Etomoxir treatment and CPT1A knockdown exacerbated the impairment of FAO caused by various stimulants (all p < 0.05). Furthermore, FAO negatively regulated HDM/cytokine-induced epithelial barrier damage, hyperactive inflammatory response, and mitochondrial dysfunction in Beas-2b cells (all p < 0.05). In contrast, treatment with L-carnitine significantly alleviated these pathophysiological features in both in vivo and in vitro models. FAO plays a protective role in the occurrence and development of asthma by maintaining airway epithelial cell homeostasis and barrier function.